SHANGHAI, March 09, 2026 — AsymBio, the biopharmaceutical CDMO subsidiary of Asymchem Group (stock code: 002821.SZ), has announced the official opening of its Fengxian commercial manufacturing facility in Shanghai. This launch completes the company’s “Golden Triangle” infrastructure in Shanghai, which integrates the Zhangjiang Science & Technology Center, the Jinshan Site, and the Fengxian Site. This network provides end-to-end CDMO services, spanning from initial R&D and process development to clinical pilot production and large-scale commercial manufacturing, streamlining the path from IND to BLA for client programs through coordinated cross-site operations.
AsymBio’s “Dual Sites + One Center” framework offers integrated capabilities across the entire biologics development cycle:
- Zhangjiang Science & Technology Center: Serving as the primary innovation hub, this center focuses on early-stage R&D and process development for antibodies, proteins, novel drug conjugates (NDCs), and other advanced therapies. It establishes and optimizes platforms for cell line development, upstream/downstream processing, and analytical methods, ensuring a smooth transition from concept to pilot and commercial manufacturing.
- Jinshan Site: This comprehensive facility provides manufacturing services ranging from clinical supply and pilot-scale production to commercial output. It handles drug substance (DS) and drug product (DP) for antibodies, protein therapeutics, ADCs, and NDCs across various clinical stages.
- Fengxian Site: A newly launched, intelligent manufacturing hub designed for large-scale commercial supply and late-stage development. Adhering to international compliance standards, the site utilizes advanced smart manufacturing systems to meet the global demand for high-quality biologics at scale.
Flexible GMP manufacturing to support capacity requirements from pilot stages to commercial supply
The manufacturing network is equipped with:
- Single-use bioreactors for antibody drug substance: 200 L / 500 L / 2,000 L
- Conjugation reactors for conjugate drug substance: 50 L / 100 L / 200 L / 500 L
- Fully automated ORABS filling lines
- Advanced lyophilization and isolator filling systems: 5 m² to 20 m² lyophilizers, supporting 2R–20R formats
These resources support a wide range of dosage forms and specifications, enhancing AsymBio’s ability to provide customized manufacturing solutions for biologics.
Leveraging Asymchem’s Payload–Linker Expertise for Integrated Drug Conjugate Services
AsymBio utilizes the broader resources of the Asymchem Group by connecting its Shanghai conjugation facilities with the Group’s payload–linker R&D and manufacturing site in Tianjin. This integrated model links Tianjin’s process development with Shanghai’s antibody DS, conjugate DS, and DP fill-finish operations. This cross-regional coordination ensures a stable supply chain and improves efficiency throughout the development process.
With the Fengxian site now operational, AsymBio’s Shanghai network covers the entire value chain from early development to commercialization. Through its “Dual Sites + One Center” model and integrated payload–linker services, the company offers global clients reliable and customized solutions to move pipelines from the lab to the market.
About AsymBio
AsymBio, a subsidiary of Asymchem Group, is a dedicated biopharmaceutical CDMO. With over 25 years of global experience, the company provides comprehensive CDMO services from early-stage development to commercial-scale manufacturing. Building on its expertise in ADCs, AsymBio is expanding into NDCs—including RDCs, AOCs, PDCs, APCs, BsADCs, and dpADCs—while maintaining robust capabilities for antibody and protein-based therapeutics.
For more information, visit or follow us on .
Business inquiries: MKT@asymchem.com.cn
Compliance Notes
Forward-Looking Statement Disclaimer: This press release contains forward-looking statements regarding future expectations. Actual results may vary due to various factors. AsymBio is under no obligation to update these statements.
Non-Solicitation Statement: This announcement is for informational purposes only and does not constitute an offer to sell or a solicitation to buy securities.
